NCT00265876 is a Phase 1, PHASE2 clinical trial of AZD0530 in Pancreatic Cancer, sponsored by NCIC Clinical Trials Group.

Who is sponsoring NCT00265876?

NCT00265876 is sponsored by NCIC Clinical Trials Group.

What drugs are being tested in NCT00265876?

Interventions in NCT00265876: AZD0530, gemcitabine hydrochloride.

What condition does NCT00265876 study?

NCT00265876 studies Pancreatic Cancer.

Is NCT00265876 still recruiting?

NCT00265876 is currently completed. Last updated 4 August 2023.

Last reviewed 2023-08-04 · How we verify

NCT00265876

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AZD0530 and Gemcitabine in Locally Advanced/Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery

Completed Phase 1, PHASE2 Last updated 4 August 2023

What this trial tests

Phase 1, PHASE2 trial testing AZD0530 in Pancreatic Cancer in 34 participants. Completed in 6 January 2012.

Timeline

26 April 2006

Primary endpoint
8 January 2009

6 January 2012

Quick facts

Lead sponsor	NCIC Clinical Trials Group
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	34
Start date	26 April 2006
Primary completion	8 January 2009
Estimated completion	6 January 2012
Sites	4 locations across Canada

Drugs / interventions tested

AZD0530 — full drug profile →
gemcitabine hydrochloride — full drug profile →

Conditions studied

Pancreatic Cancer — all drugs for Pancreatic Cancer →

Sponsor

NCIC Clinical Trials Group

Who can join

Adults 18 to 120, any sex, with Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: AZD0530 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving AZD0530 together with gemcitabine may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of AZD0530 when given together with gemcitabine and to see how well they work in treating patients with locally advanced or metastatic pancreatic cancer that cannot be removed by surgery.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

SRC: a century of science brought to the clinic.
Aleshin A, Finn RS. · · 2010 · cited 170× · PMID 20689754 · DOI 10.1593/neo.10328
Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review.
Koltai T, Reshkin SJ, Carvalho TMA, Di Molfetta D, et al · · 2022 · cited 77× · PMID 35626089 · DOI 10.3390/cancers14102486
Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer.
Egloff AM, Grandis JR. · · 2008 · cited 65× · PMID 18544443 · DOI 10.1053/j.seminoncol.2008.03.008
Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy.
Parkin A, Man J, Timpson P, Pajic M. · · 2019 · cited 40× · PMID 31330086 · DOI 10.1111/febs.15011
Functional roles of SRC signaling in pancreatic cancer: Recent insights provide novel therapeutic opportunities.
Poh AR, Ernst M. · · 2023 · cited 34× · PMID 37120696 · DOI 10.1038/s41388-023-02701-x
Dual Drug Repurposing: The Example of Saracatinib.
Ramos R, Vale N. · · 2024 · cited 17× · PMID 38674150 · DOI 10.3390/ijms25084565

Verify or expand the search:

Other recruiting trials for Pancreatic Cancer

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting

Other NCIC Clinical Trials Group trials

Trials by the same sponsor.

NCT01916187 — Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma · Phase 1 · withdrawn
NCT01830621 — BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma · Phase 3 · completed
NCT01652144 — A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma · Phase 2 · completed
NCT01627054 — A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia · Phase 2 · completed
NCT01486368 — A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00265876 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by NCIC Clinical Trials Group
Last refreshed: 4 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00265876.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing